Others have argued that excessive regulation suppresses therapeutic innovation, and that the current cost of regulator-required clinical trials prevents the full exploitation of new genetic and biological knowledge for the treatment of human disease. A 2012 report by the President's Council of Advisors on Science and Technology made several key recommendations to reduce regulatory burdens to new drug development, including 1) expanding the FDA's use of accelerated approval processes, 2) creating an expedited approval pathway for drugs intended for use in narrowly defined populations, and 3) undertaking pilot projects designed to evaluate the feasibility of a new, adaptive drug approval process. COUNT 8
QSN1 Who put out a report in 2012? ANS1 President's Council of Advisors on Science and Technology QSN2 What has been argued restricted innovation? ANS2 excessive regulation QSN3 What was a recommendations brought about from the report? ANS3 expanding the FDA's use of accelerated approval processes QSN4 What is one thing excessive regulations causes? ANS4 therapeutic innovation QSN5 What can be used to evaluate new approval processes? ANS5 pilot projects QSN6 What is excessive drug regulation said to suppress? ANS6 therapeutic innovation QSN7 In what year was a report made to reduce the burdens of drug development? ANS7 2012 QSN8 What was argued to be holding back new knowledge for treating diseases? ANS8 current cost of regulator-required clinical trials